Hercules Capital

Hercules Capital (NYSE: HTGC) today announced that it has scheduled its first quarter 2025 financial results conference call for Thursday, May 1, 2025, at 2:00 p.m. PT (5:00 p.m. ET). Hercules will release its financial results after market close that same day. Read more: https://lnkd.in/eiPysDGU

Appreciative to be asked to be on the panel again at this years Venture Debt Conference in NYC at a very compelling time in our industry. Thanks Zack Ellison for moderating an insightful panel discussion with fellow peers David Spreng, Mark Solovy and Paul Marino!

Hercules Capital has made a secured financing commitment to MoonLake Immunotherapeutics (NASDAQ: MLTX), a clinical-stage biopharmaceutical company unlocking the potential of sonelokimab, a novel investigational Nanobody® for the treatment of inflammatory disease. "We are thrilled to partner with MoonLake Immunotherapeutics and support their mission of improving treatment outcomes for patients living with inflammatory diseases," said R. Bryan Jadot, Group Head and Senior Managing Director at Hercules Capital and John Miotti, Principal at Hercules Capital. "This transaction highlights our commitment to empowering biotech companies as they navigate the critical path from clinical trials to market success." Chief Financial Officer at MoonLake Immunotherapeutics, Matthias Bodenstedt said, "We are extremely excited to partner with Hercules Capital that recognizes the value and potential of sonelokimab. We were able to secure deal terms, including a very sizable commitment and a highly competitive cost of capital. This financing facility further bolsters our already robust cash position without diluting our shareholders’ stakes and effectively removes any perceived financing overhang as we approach our pivotal data readout for the HS VELA program this summer." Read more: https://lnkd.in/eTyWfXXC

Hercules Capital has made a new debt financing commitment to Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases.   "We are proud to support Savara during this transformative time for the company," said Tom Hertzberg, Managing Director, Hercules Capital. "As Savara approaches their first potential approval with MOLBREEVI, providing this capital underscores our dedication and commitment to helping bring novel and life-changing therapies to market." "We’re pleased to partner with Hercules Capital as we work to get MOLBREEVI, a potential first-in-class therapy for aPAP, approved in the U.S. and Europe," said Matt Pauls, Chair and Chief Executive Officer, Savara. "This low-cost capital strategic financing further strengthens our financial position and provides additional flexibility following the BLA submission and as we prepare for a potential commercial launch of MOLBREEVI in the U.S." Read more: https://lnkd.in/eDZdBEkc

Hercules Capital’s Life Sciences Team supports pioneering companies advancing the future of healthcare. Our non-dilutive financing solutions help innovators fund clinical development, extend runway, pursue strategic acquisitions, and invest in commercialization — all while preserving equity. From biotechnology and specialty pharma to medical devices, diagnostics, and healthcare services, we partner with companies driving meaningful change across the life sciences landscape. Learn more about how venture debt can be a strategic resource for your next milestone: https://lnkd.in/dVjWaV6

Hercules Capital’s Technology Team partners with bold, venture-backed companies driving innovation across the tech ecosystem. Whether it’s scaling operations, entering new markets, investing in cutting-edge platforms, or optimizing capital structure ahead of IPOs or strategic transactions — we deliver flexible, non-dilutive financing to help our partners move faster. Our portfolio spans enterprise software, cybersecurity, AI, space and defense, business services, media, networking technologies, and beyond, empowering category leaders to reach the next stage of growth. Explore how venture lending can support your company’s trajectory: https://lnkd.in/eUWWwN4

At Hercules Capital, we're committed to making a difference through charitable giving and volunteering. Through volunteer leave and matching donations, we support organizations where we live and work that provide essential resources in areas such as education and healthcare, combating child poverty, and lifting up our communities. In 2024, our charitable giving including matching donations totaled $309,430.  Learn more: https://lnkd.in/e3Ge53RH

Hercules Capital, Inc. (NYSE: HTGC) (“Hercules” or the “Company”), today announced that it has agreed to sell to the initial purchasers in a private offering, $250.0 million aggregate principal amount of its 4.75% Convertible Unsecured Notes due 2028 (the “Convertible Notes”). The Company also has granted the initial purchasers an option to purchase up to an additional $37.5 million principal amount of the Convertible Notes to cover overallotments, if any. The Convertible Notes will be offered only to qualified institutional buyers (as defined in the Securities Act of 1933, as amended (the “Securities Act”)) pursuant to Rule 144A under the Securities Act. The closing of the transaction is subject to customary closing conditions and the Convertible Notes are expected to be delivered and paid for on March 10, 2025. Read more here: https://lnkd.in/g-BD7UBn

Hercules Capital is pleased to announce the promotion of Noah Carville to Managing Director. Noah is based in Boston and focuses on investment origination, diligence, and underwriting across the spectrum of the Technology market. Read more: https://lnkd.in/eW-ZW_8n

Hercules Capital is pleased to announce the promotion of Eddie Lopez to Principal. Eddie works with the Technology Group and is based in San Mateo, focusing on loan origination, venture relationships, and business development efforts. Read more: https://lnkd.in/e6gkmHhx